Statistics from Altmetric.com
It has now become possible to measure fractional flow reserve from standard coronary computed tomographic angiography.
The rapid accumulation in clinical data behind this technique has culminated in a Food and Drug Administration approval and also approval by the National Institute for Health and Clinical Excellence (NICE).
The aims of the current manuscript are to explore the scientific principles behind this technique, the published data validating its use, the potential benefits to healthcare systems and also the challenges it is likely to face as it attempts to enter the clinical domain.
Coronary computed tomographic angiography (CTA) is now established as a clinically valuable non-invasive anatomical test for the detection and exclusion of significant coronary disease. A number of prospective multicentre trials have shown coronary CTA to be an ideal test for the exclusion and detection of coronary disease using invasive angiography as the reference.1–3 Despite this, owing to its relatively low positive predictive value of 48% and inability to determine functional significance,1 its use in international guidelines has generally been restricted to patients with chest pain at a low-intermediate risk of having coronary artery disease (CAD).4 For patients at an intermediate risk of CAD, functional testing is generally indicated, and for high-risk patients, invasive coronary angiography (ICA) remains the recommended diagnostic test.
Although this strategy is designed to determine whether a patient’s symptoms are attributable to CAD, and specifically myocardial ischaemia, recent studies indicate that this approach has important flaws. In a study of almost 400 000 patients, Patel et al showed that up to 62% of the patients who underwent ICA in the USA were subsequently found to have no significant obstructive disease. Furthermore, of those patients with a positive stress test, approximately two-thirds had no obstructive disease and, conversely, 28% of the patients with a negative stress …
Contributors All authors have contributed significantly to the manuscript in either principal drafting of the manuscript, scientific literature review, critical review and editing.
Competing interests NC has received unrestricted research grants from HeartFlow, Boston Scientific, St. Jude Medical, Haemonetics, and Medtronic; honoraria/speaker fees from HeartFlow, St. Jude Medical, and Haemonetics; and travel sponsorships from Biosensors, Lilly/D-S, and Abbott Vascular. RR and NC are expert advisers to the NICE MTAC for FFRCT.
Provenance and peer review Commissioned; externally peer reviewed.
Correction notice Since this article was first published online the corresponding authors email address has been updated. The abbreviation FFA has been removed from two sections in the paper and replaced with the correct abbreviation FFR.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.